GSK plc (GSK) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary indicates strong financial performance with growth in key areas like Shingrix and Trelegy, improved operating margins, and increased free cash flow. The Q&A section highlights confidence in future revenue targets and strategic growth in oncology and respiratory areas. Despite some delays, GSK remains optimistic about its pipeline and strategic initiatives. The overall sentiment is positive, reflecting potential stock price appreciation in the short term.
Key Financial Performance
Total Sales Total sales were up 8% for the quarter, driven by sustained growth across specialty medicines in RI&I, oncology, and HIV.
Core Operating Profit Core operating profit increased by 11%, attributed to leverage and strong sales performance.
Core Earnings Per Share (EPS) Core EPS rose by 14% to 55p, reflecting strong financial performance and operational efficiency.
Cash Generation Cash generation reached GBP 6.3 billion for the year so far, supporting investments and shareholder returns.
Specialty Medicines Sales Specialty medicines sales grew by 16%, driven by strong demand in RI&I, oncology, and HIV.
Benlysta Sales Benlysta sales increased by 17%, supported by global guidelines recommending earlier use of biologics and its strong safety profile.
Nucala Sales Nucala sales grew by 14%, driven by COPD uptake and growth across all in-line indications.
Oncology Portfolio Sales Oncology portfolio sales increased by 39%, with Jemperli and Ojjaara showing strong growth.
Jemperli Sales Jemperli sales grew for the 10th consecutive quarter, driven by its differentiation as the only immuno-oncology medicine demonstrating overall survival in endometrial cancer.
Ojjaara Sales Ojjaara sales increased by 51%, driven by first- and second-line patient demand in the U.S. and volume growth in Europe.
HIV Portfolio Sales HIV portfolio sales grew by 12%, driven by strong patient demand for long-acting injectables and Dovato.
Cabenuva Sales Cabenuva sales grew by 48%, driven by strong patient demand and competitive performance in the U.S.
Shingrix Sales Shingrix sales grew by 13%, driven by strong performance in Europe and Japan.
Vaccines Sales Vaccines sales were up GBP 2.7 billion, a 2% increase, driven by Shingrix, Arexvy, and Bexsero.
Trelegy Sales Trelegy sales grew by 25%, driven by strong growth in all regions and its position as the top-selling brand for COPD and asthma globally.
Free Cash Flow Free cash flow increased by GBP 1.8 billion versus last year, driven by strong cash generation from operations and favorable tax payment phasing.
Operating Margin Operating margin improved by 90 basis points in the quarter, driven by SG&A margin improvement and sales mix benefits.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
FDA Approvals: Secured four FDA approvals this year, including BLENREP last week, with a fifth (depemokimab) expected before year-end.
New Product Launches: BLENREP approved in 8 markets, including the U.S., with significant potential in multiple myeloma treatment.
Pipeline Expansion: 15 scale opportunities with peak year sales potential of over GBP 2 billion, including depemokimab for COPD and efimosfermin for liver disease.
New Innovations: GSK'261, a monoclonal antibody for polycystic kidney disease, received orphan drug designation by the FDA.
Specialty Medicines Growth: Sales up 16%, driven by strong demand for Shingrix, Arexvy, and meningitis vaccines in Europe and the U.S.
HIV Portfolio Expansion: HIV sales up 12%, driven by long-acting injectables and Dovato, with Cabenuva growing 48%.
Oncology Portfolio Growth: Jemperli sales up for the 10th consecutive quarter, and BLENREP expected to be a material growth driver in the next 3-4 years.
Vaccines Performance: Shingrix sales grew 13%, with strong performance in Europe and Japan. Arexvy and meningitis vaccines also showed growth.
Operational Profit: Core operating profit up 11%, driven by efficiency gains and strong sales mix.
Cash Generation: Generated GBP 6.3 billion in cash year-to-date, supporting investments and shareholder returns.
Supply Chain Optimization: Investing $30 billion in R&D and advanced manufacturing in the U.S., including a new biologics flex factory in Pennsylvania.
Productivity Initiatives: SG&A margin improved by 70 bps, reflecting efficiency gains.
R&D Investment: Accelerated pipeline investment, including ADC programs and pivotal trials for efimosfermin and GSK'981.
Long-Term Outlook: Upgraded long-term sales outlook to over GBP 40 billion by 2031, supported by a stronger balance sheet.
Sustainability Initiatives: Developed a low-carbon version of Ventolin, reducing GSK's carbon footprint by up to 45%.
Business Development: Focused on pipeline expansion through acquisitions and licensing agreements, including IDRX-42 and efimosfermin.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Medicare redesign impact: The company faced challenges due to the Medicare redesign from the IRA, which impacted financial performance in the U.S. market. The impact is expected to be closer to the lower end of the GBP 400 million to GBP 500 million range.
Supply chain optimization: Efforts to optimize the supply chain to scale up capacity for new medicines and vaccines are ongoing, but challenges in execution could impact timely delivery and operational efficiency.
Market penetration for Shingrix in the U.S.: Penetration in the U.S. market for Shingrix has slowed, with immunization rates reaching harder-to-reach patients, potentially limiting further growth.
Competitive pressures in flu vaccines: The company faced competitive pressure in the flu vaccine market, particularly in targeting younger, healthier cohorts, which impacted sales.
Regulatory delays for rilpivirine Phase III trial: The rilpivirine Phase III trial supply delay has pushed the start of the Quattro registrational study to H1 2026, potentially delaying product launch timelines.
Zantac settlement payments: The company has incurred significant Zantac settlement payments, totaling nearly GBP 0.7 billion year-to-date, with an additional GBP 0.5 billion expected by year-end, impacting cash flow.
Generic competition in General Medicines: Generic competition continues to affect the General Medicines portfolio, leading to stable but not growing sales in this segment.
Adherence issues with biologics: High discontinuation rates for biologics, with up to 65% of new patients discontinuing therapy within the first 12 months, pose challenges for patient outcomes and market growth.
Economic uncertainties and IRA tariffs: The company is positioned to respond to enacted and indicated tariffs under the IRA, but these could still pose financial and operational challenges.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Expectations: GSK has upgraded its full-year sales expectations from 3%-5% to 6%-7%, driven by strong performance in Specialty Medicines, including HIV, and expects to be towards the top of the vaccines range.
Margin Projections: Core operating profit guidance has been raised to 9%-11%, and EPS guidance has been increased to 10%-12%. Gross margin is expected to benefit from product mix, partially offset by supply chain charges of around GBP 100 million in Q4.
Capital Expenditures: GSK plans to invest $30 billion in R&D and advanced manufacturing in the U.S. over the next 5 years, including the construction of a new biologics flex factory in Pennsylvania.
Specialty Medicines Growth: Specialty Medicines are expected to grow from low teens to mid-teens percentage growth for the full year, driven by strong demand in RI&I, oncology, and HIV.
Vaccines Business Outlook: Vaccines sales are expected to land towards the top of the guidance range of declining low single digit to stable. Long-term prospects for the vaccines business remain strong despite near-term caution in the U.S. market.
HIV Portfolio Growth: HIV portfolio guidance for 2025 has been upgraded from mid- to high single-digit growth to around 10%, driven by strong demand for long-acting injectables and Dovato.
Pipeline and Product Launches: GSK expects to launch 15 scale opportunities with peak year sales potential of greater than GBP 2 billion by 2031. Key launches include depemokimab for COPD patients, efimosfermin in MASH, and GSK'981 for second-line GIST.
Oncology Portfolio: The oncology portfolio is expected to be a significant growth driver, with key assets like BLENREP, Jemperli, and GSK'227 advancing in clinical trials and regulatory approvals.
Long-Acting HIV Treatments: GSK plans to launch multiple long-acting HIV treatments, including Q4M and Q6M regimens, between 2028 and 2030, with a focus on ultra-long-acting options.
General Medicines Outlook: General Medicines sales are expected to remain broadly stable in 2025, with future opportunities including the launch of low-carbon Ventolin and anti-infective portfolio expansion.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Dividend for the quarter: 16p per share
Share buyback program: £1.1 billion executed so far in 2025, with a cumulative total of £1.4 billion expected by year-end.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What are the major areas contributing to the EUR 6 billion revenue gap between market expectations in 2031 and GSK's revenue target?
A:The major areas are oncology and respiratory, immunology, and inflammation. Key assets include BLENREP, Jemperli, ADCs licensed from Hansoh, and camlipixant. Data readouts and commercial execution are expected to bridge the gap.
Q:What is the outlook for GSK's strategy and revenue targets for 2026 and 2031?
A:Management reiterated high confidence in achieving the 2026 and 2031 revenue targets. Detailed updates on the 2026 outlook will be provided with the full-year 2025 results, and further details on the 2031 targets will be shared later in 2026.
Q:What are the growth prospects for Shingrix, particularly outside the U.S.?
A:Shingrix has seen strong growth in Europe, with an average immunization rate of 9.7% in the top 10 markets outside the U.S. The strategy includes maintaining pricing discipline, expanding in Europe and Japan, and pivoting to emerging markets like China in the midterm.
Q:What is the outlook for GSK's operating expenses and margin targets?
A:GSK is confident in achieving a margin target of over 31% by 2026. R&D investment will continue to grow ahead of sales, and significant investments are being made in new launches like BLENREP and depemokimab. Productivity improvements in SG&A and gross margin are also contributing to margin growth.
Q:What is the latest update on BLENREP and depemokimab?
A:BLENREP is gaining traction, with a focus on supporting physicians and leveraging clinical experience. Depemokimab is seen as a significant opportunity, with strong market research indicating high interest among pulmonologists. The strategy focuses on new biologic-naive patients.
Q:What is GSK's approach to business development and its impact on the pipeline?
A:GSK continues to focus on disciplined business development, with recent deals contributing significantly to the pipeline. The company is prioritizing respiratory, immunology, and oncology, with about half of the pipeline coming from business development.
Q:What is the status of GSK's long-acting HIV portfolio and the impact of the Q4M delay?
A:The Q4M Phase III study start is delayed to H1 2026 due to clinical trial supply issues. However, GSK remains confident in its long-acting HIV portfolio, including Cabenuva and upcoming Q6M regimens. The delay is not expected to materially impact financial outlooks.
Q:What is the commercial impact of the Q4M delay relative to Gilead's weekly oral lenacapavir plus islatravir?
A:GSK believes the weekly oral regimen will primarily cannibalize other orals and does not see it as a significant challenge to its long-acting injectables. GSK emphasizes the importance of integrase inhibitors in HIV treatment.
Q:What are the growth prospects for Jemperli in endometrial cancer and other indications?
A:Jemperli has strong momentum in endometrial cancer, with 90% of patients now on some form of IO. GSK is also pursuing additional indications, including rectal and colon cancers, to support long-term growth.
Q:What is the outlook for Nucala in COPD and the broader COPD portfolio?
A:Nucala is performing well in COPD, with broad uptake across different eosinophil levels. GSK is also advancing its COPD portfolio with multiple Phase III studies and new mechanisms, including long-acting TSLP and IL-33 options.
Q:What is the status of GSK's general medicines and the impact of IRA negotiations?
A:GSK's general medicines outlook remains unchanged, with no updates to the 2021-2026 guidance. IRA negotiations, including for Trelegy, were in line with expectations and are fully factored into the company's outlook.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the revenue contributions of individual products to the 2031 target, the exact phasing of access for depemokimab, and the financial impact of the Q4M delay. Additionally, they did not elaborate on the pushes and pulls for the 2031 revenue target or provide detailed updates on general medicines beyond reiterating confidence in the existing guidance.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
BLENREP
CAB LA
COPD
Cabenuva
Europe
GIST
HIV
Phase III
RD
Shingrix
Ventolin
asset
cancer
carbon
charge GBP
date
demand
development
digit
efimosfermin
end
injectables
launch
line
margin
market
medicine
oncology
opportunity
option
population
potential
priority
regimen
result
royalty income
share
slide
specialty
stage
term
trial
vaccine
GSK Transcript
GSK plc (GSK) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Neutral6-3
GSK plc (GSK) Q1 2026 Earnings Call Transcript
Positive4-29
The earnings call summary and Q&A indicate positive sentiment. Specialty medicines and HIV portfolios show promising growth, supported by strong pipeline developments. The 6% dividend increase and strategic focus on operational efficiency bolster confidence. Despite some uncertainties, optimistic guidance and new product launches, such as Exdensur, provide a positive outlook. The market reaction is expected to be positive, with a 2% to 8% increase in stock price over the next two weeks.
GSK plc (GSK) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Neutral3-11
GSK plc (GSK) Q4 2025 Earnings Call Transcript
Positive2-4
The earnings call summary highlights strong growth in key areas such as Specialty Medicines, HIV, and oncology, along with upgraded revenue and EPS guidance. The Q&A session reveals strategic initiatives, especially in COPD and HIV, and addresses R&D realignment. Despite some concerns over regulatory strategies, the overall sentiment is positive, with strong financial performance and optimistic guidance suggesting a stock price increase.
GSK Slides
GSK Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
